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Abstract 
Background: The existence of an ecstasy dependence syndrome is controversial. We 
examined whether the acute after-effects of ecstasy use (i.e., the “come-down”) 
falsely lead to the identification of ecstasy withdrawal and the subsequent diagnosis of 
ecstasy dependence. Methods: The Structured Clinical Interview for DSM-IV-TR 
Disorders: Research Version (SCID-RV) was administered to 214 Australian ecstasy 
users.  Ecstasy withdrawal was operationalized in three contrasting ways: (i) as per 
DSM-IV criteria; (ii) as the expected after effects of ecstasy (a regular come-down); 
or (iii) as a substantially greater or longer come-down than on first use (intense come-
down). These definitions were validated against frequency of ecstasy use, readiness to 
change and ability to resist the urge to use ecstasy. Confirmatory factor analyses were 
used to see how they aligned with the overall dependence syndrome. Results: Come-
down symptoms increased the prevalence of withdrawal from 1% (DSM-IV criterion) 
to 11% (intense come-downs) and 75% (regular come-downs). Past year ecstasy 
dependence remained at 31% when including the DSM-IV withdrawal criteria and 
was 32% with intense come-downs, but increased to 45% with regular come-downs. 
Intense come-downs were associated with lower ability to resist ecstasy use and 
loaded positively on the dependence syndrome. Regular come-downs did not load 
positively on the ecstasy dependence syndrome and were not related to other indices 
of dependence. Conclusion: The acute after-effects of ecstasy should be excluded 
when assessing ecstasy withdrawal as they can lead to a false diagnosis of ecstasy 
dependence. Worsening of the ecstasy come-down may be a marker for dependence.  
Key words:  ecstasy, 3, 4- methylenedioxy-N-methylamphetamine, dependence, 
withdrawal, diagnosis, prevalence 
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1 Introduction  
 
An estimated 19 million people world-wide use ecstasy (United Nations Office on 
Drugs and Crime, 2013). One of the concerns about the wide-spread use of ecstasy is 
whether the drug can lead to dependence. Several epidemiological surveys have 
identified dependence among ecstasy users (Bruno et al., 2009; Cottler et al., 2009; 
Cottler et al., 2001; Topp et al., 1997; Yen and Hsu, 2007). However, the rates of 
dependence reported seem at odds with infrequent use of the drug, casting doubt on 
the validity of the diagnosis (Topp et al., 1997). A key concern is whether the 
diagnosis of ecstasy dependence has been inflated by the inclusion of the acute after 
effects of ecstasy ( referred to as the “come-down” or “crash”) as withdrawal 
symptoms (Degenhardt et al., 2010; Topp et al., 1997). The come-down reflects the 
acute recovery phase after using the drug, akin to an alcohol hangover, and distinct 
from the subsequent withdrawal syndrome (Gawin and Ellinwood, 1988).  For 
psychostimulant drugs, this crash phase occurs within 1 to 3 days of use and it is 
characterised by dysphoria, depression, lethargy, irritability, anxiety, agitation, 
hyperphagia and hypersomnelence (Davison and Parrott, 1997; Gawin and Ellinwood, 
1988; McGregor et al., 2005). 
  
Whether ecstasy use can lead to a withdrawal syndrome is controversial.  Ecstasy 
(3,4–methylenedioxymethamphetamine) is classified as a hallucinogen in the 
Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) 
(American Psychiatric Association, 2000). The diagnosis of a hallucinogen disorder 
excludes withdrawal as a criterion because hallucinogen withdrawal has not been 
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consistently documented in humans (American Psychiatric Association, 2000). 
However, ecstasy has both hallucinogenic and stimulant properties (Nichols, 1994), 
and stimulant dependence is accompanied by a withdrawal syndrome. Stimulant 
withdrawal is characterised by dysphoric mood (e.g., depression, irritability, anxiety) 
and accompanied by fatigue, insomnia and psychomotor agitation (American 
Psychiatric Association, 2000); the acute phase lasts for 7-10 days and residual 
symptoms can persist for several weeks (McGregor et al., 2005). 
 
Self-reported withdrawal symptoms have been documented following ecstasy use in 
epidemiological studies (Yen and Hsu, 2007), but the extent to which these reports 
reflect the expected acute after-effects of ecstasy use (i.e., the come-down)  is unclear 
(Topp et al., 1997). The acute come-down from ecstasy is characterised by the same 
symptoms as stimulant withdrawal (e.g., lethargy, moodiness, insomnia, depression, 
irritability, and paranoia.(Davison and Parrott, 1997)), and has a similar timeframe 
(several days) to the early phase of withdrawal, making it difficult to differentiate 
between the two conditions. For this reason, the acute phase of stimulant withdrawal 
manifests clinically as a more intense and longer stimulant come-down (McGregor et 
al., 2005).  In line with this, many stimulant users report a worsening of the come-
down symptoms over the course of their using history (Topp et al., 1997).  
 
The gold standard for diagnosing ecstasy withdrawal and making a subsequent 
diagnosis of ecstasy dependence is the Structured Clinical Interview for DSM 
Disorders (SCID), a semi-structured interview delivered by an experienced clinician 
or trained mental health professional (First et al., 2002). However, most research that 
has been conducted on ecstasy withdrawal and dependence relies on instruments that 
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can be delivered by lay-persons, such as the Composite International Diagnostic 
Interview (CIDI). While these type of instruments produce sufficiently valid 
prevalence estimates for most major psychiatric conditions (Haro et al., 2006), they 
rely on a set scripted questions, which removes the capacity for clinical judgement.  
 
In the case of diagnosing ecstasy withdrawal, lay-administered diagnostic tools, such 
as the CIDI, are problematic in that they do not distinguish between the acute come-
down from ecstasy use and the more lasting withdrawal syndrome. For example, the 
CIDI  asks respondents whether they have experienced any symptoms indicative of 
withdrawal after they “stopped or cut down” on their use; this leaves open the 
possibility that symptoms occurred after a single episode of use (i.e., reflecting the 
acute come-down from using ecstasy). In contrast, the diagnosis of ecstasy 
dependence in the DSM-IV requires that stimulant withdrawal occurs after a period of 
heavy and prolonged use (American Psychiatric Association, 2000), which  should 
avoid confounding by the acute after-effects of ecstasy among infrequent users of the 
drug. However, without this condition, come-down symptoms could contribute to the 
ecstasy withdrawal criterion, and could lead to a false diagnosis of ecstasy 
dependence. This could account for the seemingly high rates of dependence 
documented using the CIDI, such as the 59% lifetime prevalence found by Cottler and 
colleagues (Cottler et al., 2009): a finding that hinged on 68% of the sample reporting 
ecstasy withdrawal.   
 
The aim of this study was to determine what impact the acute after-effects of ecstasy 
use (i.e., the come-down) have on the identification of ecstasy withdrawal and 
whether they falsely increase the number of people diagnosed with ecstasy 
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dependence. To achieve this aim we examined the impact of using three different 
definitions of ecstasy withdrawal on the diagnosis of ecstasy dependence: (i) DSM-IV 
criteria; (ii) a regular come-down (any symptom of withdrawal experienced after 
using ecstasy); or, (iii) an intense come-down (substantially greater or longer in 
duration than on first use). Each of these definitions of ecstasy withdrawal was 
validated against a diagnosis of ecstasy dependence that excluded the withdrawal 
criterion (as per a diagnosis of hallucinogen dependence) and other indicators of 
dependence (severity of ecstasy dependence on the Severity of Dependence Scale, 
frequency of ecstasy use, inability to resist the urge to use ecstasy and readiness to 
change). A confirmatory factor analysis was used to examine whether these 
definitions were aligned with the common single dimension underpinning the 
dependence syndrome. 
 
2 Method 
2.1 Participants 
Participants were 214 ecstasy users who were recruited to a multi-site group 
randomized controlled trial (the E-Checkup, n = 160) [Australia and New Zealand 
Clinical Trial Registry Number 12611000136909] and a randomised trial conducted at 
the University of New South Wales (n = 54) [Australia and New Zealand Clinical 
Trial Registry no, 12611000180910]. Both trials assessed the efficacy of a health 
intervention for ecstasy users.  Inclusion criteria for both studies were being fluent in 
English, over 16 years of age (over 18 years of age for trial 12611000180910) and 
having used ecstasy three times in the past 90 days. Exclusion criteria for both studies 
were current moderate or severe dependence on other drugs (excluding cannabis and 
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tobacco) as assessed using the (SCID-RV) (First et al., 2002), having received 
treatment for substance use in the past 90 days, and showing evidence of medical or 
cognitive impairment or severe psychiatric illness that would interfere with 
participation.  
 
Recruitment took place between October 2009 and April 2012.  Participants were 
recruited by advertisements in free street press and magazines, postings on social 
networking and help-seeking internet sites, referrals from treatment and other health 
services, and flyers in entertainment venues. 
 
Data were collected at the baseline phase of the trial in a face-to-face interview 
conducted at the National Drug and Alcohol Research Centre, UNSW and the 
Institute of Health and Biomedical Innovation, Queensland University of Technology. 
Participants were reimbursed $25 for the interview.  Interviewers were clinical 
psychologists or clinical psychology students who were trained on the SCID-RV by 
LH or MN. Ethics approval for the study was obtained from the Human Research 
Ethics Committees, University of New South Wales, Queensland University of 
Technology and relevant NSW Area Health Service institutional ethics committees.  
 
 
2.2 Measures  
2.2.1 Ecstasy dependence 
Ecstasy dependence in the past year was assessed using the Structured Clinical 
Interview for DSM-IV Axis I Disorders – Research Version (SCID-RV) (First et al., 
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2002). The diagnosis of ecstasy dependence was initially made excluding the 
withdrawal criterion, as would be done for hallucinogen dependence. The diagnostic 
criteria were then adjusted to include the withdrawal criterion defined either 
according to the DSM-IV, as a regular come-down, or as an intense come-down. 
 
2.2.2 Definitions of ecstasy withdrawal 
Ecstasy withdrawal was assessed using the SCID-RV. Using the SCID-RV, the DSM-
IV criteria for the withdrawal syndrome was operationalized as three or more 
symptoms characteristic of withdrawal after ceasing heavy and prolonged use of 
ecstasy (American Psychiatric Association, 2000). Heavy prolonged use was defined 
as “multiple days of continuous use”.  As part of the SCID-RV interview, participants 
were instructed about the nature of ecstasy withdrawal symptoms. These symptoms 
included: autonomic hyperactivity; psychomotor agitation or retardation; insomnia or 
hypersomnia; fatigue; nausea, vomiting, or changes in appetite; transient visual, 
tactile, or auditory hallucinations or illusions; muscle aches; anxiety; vivid, unpleasant 
dreams; and dysphoria. Participants who endorsed at least one withdrawal symptom in 
SCID-RV but did not meet the criteria for DSM-IV withdrawal were classified as 
having a come-down. Participants were then asked whether the come-down that they 
experienced was "substantially greater or longer in intensity than on first use". 
Participants who indicated that their come-downs were substantially greater or more 
intense than on first use were classified has having an "intense come-down" while 
those who did not were classified as having a "regular come-down". 
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2.2.3 Ecstasy use and severity of ecstasy dependence 
Ecstasy use in the past 90 days was assessed using the Time Line Follow-Back 
(Sobell & Sobell, 1992). The Severity of Dependence Scale (Gossop et al, 1992) was 
used to assess severity of dependence on ecstasy in the past three months in addition 
to the SCID-RV. 
 
2.2.4 Ability to resist the urge to use ecstasy 
Ability to resist the urge to use ecstasy was assessed using the Drug Taking 
Confidence Questionnaire – 8 (DTCQ – 8) (Sklar & Turner, 1999). The DTCQ-8 asks 
participants to imagine themselves in eight high-risk situations and indicate on a six-
point scale (0% – not at all confident to 100% – very confident) how confident they 
are that they would be able to resist the urge to use ecstasy in that situation. Higher 
scores indicate greater confidence in resisting the urge to use ecstasy. 
 
2.2.5 Readiness to change ecstasy use 
Readiness to change was assessed using the University of Rhode Island Change 
Assessment Scale (McConnaughy et al., 1983). This is a 32-item self-report measure 
that defines four conceptual stages of change (precontemplation, contemplation, 
action, and maintenance). The readiness to change score is calculated by summing the 
mean score for the contemplation, action, and maintenance subscales and subtracting 
the mean score for the precontemplation subscale. The readiness to change score 
ranges from − 2 to +14, with higher scores indicating greater readiness to change 
(DiClemente et al., 2004).  
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 Other measures 
The use of alcohol and other major drug types was assessed in the past 90 days using 
the Brief Treatment Outcome Measure (Lawrinson et al., 2005). Demographics 
included age, sex, sexual orientation, marital status, country of birth, language spoken 
at home and employment status. 
 
2.3 Analysis 
Descriptive comparisons of groups were made using t-tests for normally distributed 
continuous data, a comparison of medians test for non-parametric continuous data, 
and a Pearson’s Chi Square test for categorical data. Logistic regression was used to 
adjust for between groups differences in covariates. Medians and inter-quartile ranges 
are reported for skewed data. All tests were two-sided with significance set at p < 
0.05. These data analyses were conducted using Stata SE Version 11.2(Stata 
Corporation, 2011).  
 
Binary confirmatory factor analyses, applying a unifactorial model of dependence 
items (consistent with those found for all other substances of dependence 
(Morgenstern et al., 1994; Nelson et al., 1999)), were used to compare the fit for the 
syndrome using each of the three definitions of withdrawal. Robust maximum 
likelihood techniques were applied in Mplus 7.1. In addition, analyses were replicated 
using the mean and variance adjusted weighted least squares extraction procedure 
used for estimation. Model fit indices of root mean square residual (RMSEA), 
weighted root mean square residual (WRMR) and comparative fit index (CFI) were 
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examined. For categorical data, values of RMSEA <0.06, WRMR <0.90 and CFI 
>0.95 are considered to indicate good model fit (Schrieber et al., 2006). 
 
3 Results  
3.1 Participant characteristics 
Participants had a median age of 22.5 years (inter-quartile range 18-46 years), 66% 
were male, 34% were female, and one participant was transgender. The majority were 
employed (67%), but mostly in part-time or casual work (43% of the total sample), 
with the remainder being unemployed (22%) or studying (11%). They had a median 
of 14 years education (inter-quartile range 9-20 years) and 23% had completed a 
university degree. The majority were single (57%) or dating (30%), with only 12% 
married or co-habiting with a partner. Twenty-seven per cent were born outside of 
Australia, 9% were from a non-English speaking background and less than 1% 
identified as aboriginal or Torres Strait Islander. 
 
3.2 Ecstasy and other drug use 
Participants first used ecstasy at a median age of 18 years (inter-quartile range 14 to 
26 years). They had used on a median of 6 days (inter-quartile range 3 to 22 days) 
over the past three months, having consumed a median of 11 ecstasy pills during this 
time (inter-quartile range 3 to 55 pills). The use of other psychostimulants was 
common (any use in the past 90 days: amphetamines 38%, cocaine 37%); as was the 
use of hallucinogens (35% in the past 90 days); while the use of sedative and 
depression drugs was less common (Table 2). Almost all drank alcohol in the past 90 
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days, with patterns of alcohol use typical of weekend drinking, 70% had smoked 
cannabis during this time and half had smoked tobacco. 
 
3.3 Ecstasy withdrawal  
Only 1% of the sample met DSM-IV criteria for withdrawal in the past year; 11% met 
criteria for intense come-downs, and 75% for regular come-downs (Table 1). This 
compared to between 17% and 42% of participants meeting the criteria for other 
dependence symptoms (Table 1).  
 
3.4 Impact of ecstasy withdrawal definitions on the diagnosis of ecstasy 
dependence 
Thirty one per cent of participants met DSM-IV criteria for ecstasy dependence in the 
past year when excluding withdrawal as a criterion (Table 2). Including the DSM-IV 
criteria for withdrawal did not change the past year prevalence of ecstasy dependence.  
Defining withdrawal as intense come-downs increased the past year prevalence of 
ecstasy dependence by only 1% (i.e., from 31% to 32%). However, defining 
withdrawal as a regular come-down increased past year prevalence of ecstasy 
dependence to 45% (Table 2). 
 
3.5 Validity of the ecstasy withdrawal criteria  
Relative to participants who had no come-down or withdrawal (n = 54), participants 
who had regular come-downs (n = 133) were no more likely to meet DSM-IV criteria 
for ecstasy dependence when excluding the withdrawal criteria. There were no 
differences between these groups on their level of ecstasy use, self-reported severity 
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of ecstasy dependence, their ability to resist the urge to use ecstasy or their readiness 
to change their ecstasy use (Table 2).   
 
In contrast, participants who reported intense come-downs (n = 24) were significantly 
more likely to meet DSM-IV criteria for ecstasy dependence when excluding the 
withdrawal criteria. These participants were more likely to have met the dependence 
criteria for loss of control, pre-occupation, functional impairment and use despite 
harms. Individuals who had intense comedowns also reported a lower ability to resist 
using ecstasy (Table 2).  
 
Participants who experienced intense come-downs did not differ significantly on their 
demographic or illicit drug and alcohol use from participants who reported no come-
downs. However, they were more likely to smoke tobacco (Table 2). Of the factors 
related to intense come-downs, tobacco smoking was not significantly related to the 
ability to resist using ecstasy, or to the dependence criteria for functional impairment 
and pre-occupation (p > 0.05). However, tobacco smoking was related to meeting 
DSM-IV criteria for ecstasy dependence when excluding the withdrawal criteria, the 
dependence criteria of use despite harms and loss of control, making it a potential 
confound for these outcomes. After adjustment for tobacco smoking, intense 
withdrawals were still related to meeting DSM-IV criteria for ecstasy dependence 
(OR 2.1, 95% CI 1.2 – 3.6, p = 0.006), continuing to use despite harms (OR 2.5 95% 
CI 1.4 – 4.2 p = 0.001) and there remained a non-significant trend with loss of control 
(OR  1.6, 95% CI 1.0 – 2.8, p = 0.068). 
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Of the three participants who met the DSM-IV criteria for withdrawal (not reported in 
Table 2), two met DSM-IV criteria for ecstasy dependence when excluding the 
withdrawal syndrome. 
 
 
3.6 Impact of different withdrawal criteria on the structure of the dependence 
syndrome 
 
Excluding the withdrawal criterion, the remaining symptoms of dependence loaded in 
a positive and significant way onto a single factor, suggesting the presence of a 
unidimensional structure for the dependence syndrome (Table 3). All fit statistics 
indicated a good model fit for this unidimensional structure (Table 3). The inclusion 
of both the DSM-IV criteria and the ‘intense comedown’ criteria for withdrawal 
retained a good model fit, based on chi-squared indices of fit and other indices of fit 
(Table 3). This suggests that including intense come-downs as a criterion for 
dependence does not compromise the integrity of the unidimensional structure of the 
dependence syndrome. The DSM-IV withdrawal criteria loaded positively with the 
dependence syndrome factor, suggesting that it was related to this core syndrome,  
but this loading was not significant, which may be because there were only three 
participants who met the DSM-IV criteria for withdrawal. The intense comedown 
criteria for withdrawal had a moderate and significant loading with the overall 
dependence syndrome factor, again suggesting that it was related to the underlying 
dependence syndrome. However, the regular come-down definition of withdrawal 
resulted in reduced model fit across all indices of model fit and a non-significant (and 
inverse) relationship between the withdrawal item and the underlying dependence 
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syndrome factor. This suggests that the regular come-down was not related to the 
dependence syndrome as reflected through the other dependence criteria.  
 
 
 
4 Discussion  
 
These results suggest that the expected after-effects of ecstasy use (i.e., symptoms of 
the ecstasy come-down) should be excluded when diagnosing ecstasy withdrawal. 
Including these symptoms inflated the prevalence of ecstasy dependence from 31% to 
45%; they were not significantly associated with other indicators of dependence on 
the drug; and, they did not load significantly on the underlying dependence syndrome, 
suggesting that they do not form part of this syndrome. DSM-IV withdrawal and 
intense come-downs were more clearly related to dependence on ecstasy in that they 
showed a good structural fit with the dependence syndrome. Their inclusion in the 
diagnosis had negligible impact on the prevalence of ecstasy dependence. 
 
On this basis we recommend that future epidemiological studies should continue to 
assess withdrawal, in the interest of understanding whether an ecstasy withdrawal 
syndrome exists, but that the expected after-effects of using ecstasy should be 
excluded from the ecstasy withdrawal criterion when diagnosing ecstasy dependence 
and reporting consequent prevalence rates. At the least, the prevalence of dependence 
with or without the withdrawal syndrome should be reported in order to provide 
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readers with an estimate of the extent to which the withdrawal criterion contributed to 
the prevalence of ecstasy dependence.   
 
Modifications to epidemiological instruments, such as the CIDI, need to be 
considered to ensure that the expected after-effects of ecstasy do not contribute to the 
DSM-IV withdrawal criterion. Simple modifications to the instrument could achieve 
this end. For example, the wording of the question used to assess withdrawal from 
illicit substances could be changed from “When you stopped or cut-down on any of 
these [substances]” to the wording used to assess alcohol withdrawal in the CIDI, that 
is, “I’m going to ask you about some problems you might have had in the past 12 
months after you quit or cut down”), where it is clear that the respondent must have 
tried to quit or cut-down on their use, and where they have the option of “never quit” 
(an option that is not available in the illicit substance use module of the CIDI). In 
addition, a qualifier could be included to ensure that the respondent had quit or cut-
down after a period of heavy or prolonged use. Changes to this effect would reduce 
the risk that respondents would endorse symptoms that occurred only following acute 
use of the drug.  
 
Further research is needed to confirm whether intense come-downs, which appear to 
be a marker for ecstasy dependence, reflect a withdrawal syndrome, and if so, how 
they might be incorporated into the measurement of the ecstasy dependence 
syndrome. We found that participants who reported these intense come-downs were 
more likely to be dependent on ecstasy according to other criteria and they also 
reported a reduced ability to resist the urge to use ecstasy. However, the small number 
of people who reported intense come-downs in the current sample (24 participants) 
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limits the robustness of these findings and reduced our capacity to detect relationships 
between intense come-downs and other indices of dependence (including frequency of 
ecstasy use). These more intense come-downs may merely reflect long-term ecstasy 
users taking greater doses of ecstasy than when they first used the drug and therefore 
experiencing greater after-effects from their use (Parrott, 2005).  
 
The finding that symptoms of ecstasy dependence loaded onto a single dimension is 
consistent with the unidimensional nature for dependence found for other drugs, 
including alcohol, cocaine, cannabis and opioids (Nelson et al., 1999). While this 
finding lends support to the notion of an ecstasy dependence syndrome akin to that 
found for other drugs of dependence, our primary objective in undertaking this 
confirmatory factor analysis was to determine whether withdrawal symptoms were 
aligned with other symptoms of dependence, not to examine the dimensional structure 
of dependence per se. We did not explore the possibility that the two factor structure, 
proposed by previous researchers (Bruno et al., 2009; Topp et al., 1997), might 
provide a better fit for our data (these two factors reflecting ‘compulsive use’ [use 
despite problems, giving up important activities because of ecstasy, unsuccessful 
attempts to stop, withdrawal and excessive time spent obtaining or using] and 
‘escalating use’ [tolerance, and using more or for longer than intended]). Scant 
research has examined the factor structure of ecstasy dependence (Degenhardt et al., 
2010), and further research will be necessary to confirm whether the symptoms of 
ecstasy dependence are best conceptualised as being unidimensional or as having two 
distinct underlying dimensions.  
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4.1.1 Limitations and considerations 
The application of these findings to a DSM-5 diagnosis of an “ecstasy use disorder” is 
obviously limited. A diagnosis of a stimulant use disorder in the DSM-5 includes all 
of the dependence criteria in the DSM-IV plus three of the four DSM-IV criteria for 
substance abuse (failure to fulfil role obligations; continued use despite persistent or 
recurrent social/interpersonal problems; recurrent use in physically hazardous 
situations) and the additional criterion of craving (American Psychiatric Association, 
2013). The criteria for a hallucinogen use disorder differ only in that the criteria of 
withdrawal is absent (in keeping with the DSM-IV definition of hallucinogen 
dependence (American Psychiatric Association, 2000)).  With only two symptoms 
required to meet the DSM-5 criteria for a substance use disorder, the importance of 
falsely endorsing the withdrawal criterion is even more critical for the DSM-5 than 
for the DSM-IV.  
 
Caution is needed when applying our findings about the inflation of the ecstasy 
dependence diagnosis to other studies because our definition of withdrawal differed 
from that used by other researchers (e.g., Cottler and colleagues required at least 3 
withdrawal symptoms to be reported for the criterion of withdrawal to be met (Cottler 
et al., 2009) cf. only one symptom in the current study being required to meet the 
definition of a come-down).  We were also unable to confirm that the DSM-IV 
version of withdrawal was aligned with the overall dependence syndrome because 
only three participants met the DSM-IV criteria for withdrawal. 
 
Although our findings highlight intense come-downs as a potential marker for ecstasy 
dependence, the concept of intense come-downs is relatively new and requires further 
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validation. There has been limited research documenting the symptoms of the ecstasy 
come-down (Davison and Parrott, 1997; Topp et al., 1997; Verheyden et al., 2003), 
and only one previous study has documented their worsening with ongoing ecstasy 
use (Topp et al., 1997). In the absence of validated definitions, we relied on 
participants’ subjective reports as to whether or not their come-down was 
"substantially greater or longer in intensity than on first use".  Further research needs 
to examine whether this apparent worsening reflects a change in the nature of come-
down symptoms, a worsening of the same symptoms, and/or a change in the duration 
of the symptoms. 
 
Ecstasy pills in Australia often contain other drugs, including 
methylendioxyethylamphetamine (MDEA) and the potent stimulant 
methamphetamine, while the amount of MDMA contained in ecstasy pills varies 
considerably (Morefield et al., 2011).  The purity of MDMA seizures made in 
Australia was also relatively low during our study period (e.g., 10-30%) (Sindicich 
and Burns, 2013) and there was a concurrent trend toward the presence of other novel 
psychoactive substances on the Australian drug market (e.g., methcathinone) (Bruno 
et al., 2012).  However, a study by Morefield et al. examined plasma drug levels in a 
sample of recreational ecstasy users in Australia around the time of our recruitment, 
and they concluded that MDMA was the major active ingredient in ecstasy pills, 
despite variation in the content of MDMA and the presence of other drugs (Morefield 
et al., 2011). Nonetheless, the presence of methamphetamine in ecstasy pills may have 
increased rates of withdrawal and dependence in our sample relative to other studies 
of ecstasy dependence; low purity levels may have led to reports of tolerance (with 
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people needing to use more pills to get the same effect);  and, the presence of other 
drugs in ecstasy pills may have contributed to withdrawal symptoms.  
 
A further issue is the impact of poly-drug use. While there were high rates of 
polydrug use in this sample, it is unlikely that the use of other drugs, including 
psychostimulants, accounted for ecstasy withdrawal because their use did not differ 
between participants who reported intense come-downs, regular come-downs or no 
come-down after using ecstasy. Although tobacco use was more common among 
participants who reported intense come-downs, tobacco use did not account for the 
relationship between intense-come downs and other symptoms of dependence. 
 
In conclusion, the acute after effects of ecstasy use (i.e., the come-down) should be 
excluded when diagnosing ecstasy withdrawal because these symptoms do not reflect 
dependence and they falsely increase the prevalence of ecstasy dependence. Including 
either the DSM-IV withdrawal criteria, or including symptoms of come-downs that 
are more intense than would be expected from an acute dose of ecstasy, had little 
impact on the prevalence of ecstasy dependence. Further research is needed to 
understand whether the worsening of come-downs with ongoing ecstasy use reflects 
the development of an ecstasy withdrawal syndrome.  
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Table 1. Impact of changing the definition of withdrawal on the past year prevalence 
of ecstasy dependence 
 
 
Past year dependence 
criterion  
Past year diagnosis of 
ecstasy dependence 
n % (95% CI) n %  (95% CI) 
Tolerance 83 39 32 – 46    
Loss of control 68 32 26 – 39    
Unsuccessful attempts to reduce use 37 17 13 – 23    
Pre-occupation 88 42 35 – 48    
Functional impairment 44 21 15 – 27    
Use despite harms 67 34 25 – 38    
       
Withdrawal excluded from diagnosis  N/A  67 31  (25 – 38) 
Withdrawal definition:       
 DSM-IV criteria 3 1 (0 – 4) 67 31  (25 –38) 
 Intense come-down 27 11 (7 – 16) 69 32  (26 – 39) 
 Regular come-down 160 75 (68 – 80) 96 45  (38 – 52) 
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Table 2. A comparison on participant characteristics by DSM-IV criteria for 
withdrawal 
 No come-
down/ 
withdrawal 
(n = 54) 
Regular 
come-
down  
(n = 133) 
Intense 
come-
down  
(n = 24) 
Ecstasy dependence (withdrawal excluded) (%)  24  28  63** 
Dependence symptoms reported (%)    
 Tolerance  45  33  54 
 Loss of control  28  29  58* 
 Unsuccessful attempts to reduce use  17  16  25 
 Pre-occupation  33  41  63* 
 Functional impairment   9  23*  29* 
 Use despite harms  23  28  67*** 
Ecstasy use in the past 90 days (median)    
 Days of use  6.0 5.0 7.0 
 No. pills used  11.5 10.0 15.5 
Severity of Dependence Scale score (median) 2.0 2.0 3.0 
Readiness to change score (median) 5.6 5.9 6.0 
Resist the urge to use ecstasy (median) 72.5 72.5 62.5* 
Demographics    
 Age (mean)  24  24  23 
 Male (%)  69  68  57 
 Years of education (median)  14  14  13 
 Heterosexual (%)  85  83  71 
 Married (%)  13  12   8 
 Unemployed (%)  21  23  13 
 Immigrant (%)  31  23  38 
 Non-English speaking background (%)   8  11   8 
Alcohol use in the past 90 days (median)    
 Days drunk alcohol per week    2   2   2 
 Drinks per occasion   5   4   6 
 Drinks per week  15  15  20 
Other drugs used in the past 90 days (%)    
 Tobacco   39  50  67* 
 Cannabis  78  69  58 
 Amphetamines  41  36  46 
 Cocaine  39  36  46 
 Hallucinogens  42  30  50 
 Heroin   2   2   0 
 Benzodiazepines  13  13   8 
 Inhalants  15  10   8 
Note. Significance values reflect comparisons with the “No come-down/withdrawal” 
group 
*p < 0.05, **p < 0.01, ***p < 0.001 
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Table 3. Confirmatory factor analysis showing the impact of each withdrawal criterion on a unidimensional structure of ecstasy dependence. 
 Withdrawal criterion 
excluded from diagnosis 
Withdrawal criterion included in diagnosis 
DSM-IV criteria Intense come-down Regular come-down 
Loading p value Loading p value Loading p value Loading p value 
Criteria for dependence         
 Tolerance 0.534 <0.001 0.534 <0.001 0.533 <0.001 0.543 <0.001 
 Withdrawal         
 DSM-IV criteria   0.372 0.363     
 Intense come-down     0.475 <0.001   
 Regular come-down       -0.115 0.258 
 Loss of control  0.709 <0.001 0.706 <0.001 0.709 <0.001 0.715 <0.001 
 Inability to reduce use 0.701 <0.001 0.700 <0.001 0.680 <0.001 0.703 <0.001 
 Pre-occupation 0.687 <0.001 0.682 <0.001 0.688 <0.001 0.681 <0.001 
 Functional impairment 0.742 <0.001 0.747 <0.001 0.725 <0.001 0.732 <0.001 
 Continued use despite harms 0.595 <0.001 0.598 <0.001 0.623 <0.001 0.597 <0.001 
Fit statistics         
 χ2# 60.58 0.15 127.22 0.15 131.45 0.10 134.30 0.07 
 AIC# 1390.42  1424.97  1536.34  1673.02  
 BIC# 1430.76  1472.03  1583.40  1720.08  
 SSA-BIC# 1392.73  1427.67  1539.03  1675.72  
 CFI 0.993  0.989  0.981  0.977  
 RMSEA 0.031  0.029  0.042  0.045  
 WRMR 0.586  0.608  0.695  0.708  
#using the robust MLR estimator (maximum likelihood estimation with robust standard errors), AIC=Akaike Information 
Criterion;BIC=Bayesian Information Criterion, SSA-BIC=Sample-size Adjusted Bayesian Information Criterion ; ^using the WLSMV 
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(weighted least squares estimator with degrees of freedom adjusted for means and variances) estimator, CFI=Comparative Fit Index; 
RMSEA=Root Mean Square Error of Approximation, WRMR=Weighted Root Mean Residual. For categorical data, values of RMSEA <0.06, 
WRMR <0.90 and CFI >0.95 are considered to indicate good model fit (Schrieber et al., 2006). 
 
